Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29108902 | 0.97 | CA2 (0.33) | CA2HTTTSHRTDP1 | |
| SCHEMBL27800171 | 0.97 | CA2 (0.33) | CA2HTTTSHRTDP1 | |
| SCHEMBL27446117 | 0.97 | CA2 (0.33) | CA2HTTTSHRTDP1 | |
| SCHEMBL28497119 | 0.95 | CA2 (0.32) | CA2HTT | |
| SCHEMBL29025507 | 0.92 | CA2 (0.30) | CA2HTT | |
| Sulfuric Acid SCHEMBL27572300 | 0.92 | CA2 (0.30) | CA2HTT | |
| Ammonia Solution, Strong SCHEMBL28754054 | 0.92 | CA2 (0.30) | CA2HTT | |
| Bicarbonate SCHEMBL27470696 | 0.79 | — | — | |
| SCHEMBL27570830 | 0.79 | — | — | |
| SCHEMBL15643539 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569246-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | Synergy Pharamaceuticals Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. | 2013-09-19 | — | — | US | disclosed |
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | ROEMER TERRY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130116199-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2013-05-09 | — | — | US | disclosed |
| CN-102939095-A | Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials | MERCK SHARP & DOHME | 2013-02-20 | — | — | CN | disclosed |
| EP-2544528-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2544702-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120245201-A1 | Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-09-27 | — | — | US | disclosed |
| WO-2011112441-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112435-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011011528-A1 | ISOPROPYLPHENIDATE FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND FATIGUE-RELATED DISORDERS AND CONDITIONS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-01-27 | — | — | WO | disclosed |
| US-4305938-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | RCE1, POLE3, MCRS1 | CA2 4217/4885HTT 4391/4885TSHR 4210/4885 |
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | SPPL2B, ENGASE, PEPD | CA2 3948/4885HTT 4825/4885TSHR 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.